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Abstract
Background: Golestan Province in northeastern Iran has one of the highest incidences of esophageal squamous cell
carcinoma (ESCC) in the world with rates over 50 per 100,000 person-years in both sexes. We have analyzed TP53 mutation
patterns in tumors from this high-risk geographic area in search of clues to the mutagenic processes involved in causing ESCC.
Methodology/Principal Findings: Biopsies of 119 confirmed ESCC tumor tissue from subjects enrolled in a case-control
study conducted in Golestan Province were analyzed by direct sequencing of TP53 exons 2 through 11.
Immunohistochemical staining for p53 was carried out using two monoclonal antibodies, DO7 and 1801. A total of 120
TP53mutations were detected in 107/119 cases (89.9%), including 11 patients with double or triple mutations. The mutation
pattern was heterogeneous with infrequent mutations at common TP53 ‘‘hotspots’’ but frequent transversions potentially
attributable to environmental carcinogens forming bulky DNA adducts, including 40% at bases known as site of
mutagenesis by polycyclic aromatic hydrocarbons (PAHs). Mutations showed different patterns according to the reported
temperature of tea consumption, but no variation was observed in relation to ethnicity, tobacco or opium use, and alcoholic
beverage consumption or urban versus rural residence.
Conclusion/Significance: ESCC tumors in people from Golestan Province show the highest rate of TP53 mutations ever
reported in any cancer anywhere. The heterogeneous mutation pattern is highly suggestive of a causative role for multiple
environmental carcinogens, including PAHs. The temperature and composition of tea may also influence mutagenesis.
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Introduction
Esophageal Cancer is common in Persia (current Iran) at least
since the writings of the famous Iranian physician Avicenna (980–
1037), who provided one of the earliest descriptions of this disease
[1]. Since then, several authors have documented this pathology in
a broad region extending from the eastern shores of the Caspian
Sea to Central China, forming the ‘‘Central Asian Esophageal
Cancer Belt’’ [2]. This region concentrates over half of the cases of
esophageal squamous cell carcinoma (ESCC) detected in the world
[2]. Other regions of high incidence have been identified in
southern and eastern Africa and parts of South America [3]. In the
high–incidence areas of northern Iran (Golestan) and central
China, incidence rates of 50 to 100 per 100,000 person-years have
been reported, as compared to rates varying between 2 and 30 per
100,000 person-years in Europe and the United States [4]. In
Western countries, consumption of tobacco and alcohol, alone or
in combination, are the main risk factors, and there is an excess of
cases in males in agreement with the higher prevalence of these
risk factors among men [3,4]. In Golestan, however, tobacco and
alcohol do not seem to play a prominent role [5,6] and the best
documented risk factors are the consumption of hot beverages [7],
low socio-economic status [8] and, possibly, cultural or lifestyle
habits such as the use of opium derivatives [5,9]. However, these
risk factors only partially explain the high incidence rates, and the
main carcinogen(s) involved have not been identified. Given the
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late detection and poor cure rate of ESCC, the main hope for
reducing mortality lies into prevention based on a better
understanding of the specific causes of this cancer.
In several cancers, the tumor suppressor gene TP53 (OMIM #
191170) shows patterns of mutations reflecting particular muta-
genic exposures [10]. For example, in lung tumors from heavy
smokers, a common pattern of transversions occurring at G:C
bases (G:C to T:A) is often detected [11]. These transversions are
located at defined codons (mainly 157, 158, 245, 248 and 273)
which have experimentally been demonstrated to be sites for DNA
adduct formation by B[a]P metabolites [11–13]. In ESCC, studies
of TP53 mutation patterns have shown significant differences
between cancers from low and high incidence areas. In 2001, two
studies reported a description of TP53 mutation patterns in
retrospective series of ESCC from referral hospitals in Tehran,
Iran, an area with medium risk of ESCC. Compared to ESCC
from elsewhere, tumors from Tehran had significantly higher rate
of G:C to A:T transitions at CpG dinucleotides, a mutation type
commonly detected in cancers associated with inflammatory
conditions [14,15]. However, no systematic study has been
performed to assess TP53 mutation patterns in ESCC from
Golestan Province, the center of the high risk region.
In this study, we used tumor tissues from ESCC cases with
detailed annotations on pathology, individual history of exposure
and ethnicity to assess TP53 mutation patterns by sequencing and
p53 protein expression by immunohistochemistry (IHC). We
report the highest rate of somatic TP53 mutations ever reported
for any cancer, further supporting the notion that ESCC in this
area develops as the consequence of heavy exposure to
environmental mutagens, and providing molecular clues for
potentially preventable risk factors.
Results
Patients
Figure 1 summarizes the analyses conducted on ESCC cases from
Golestan. Of the initial 160 biopsies, each from a different patient,
DNA was successfully amplified for all TP53 coding exons in 119.
These patients were selected as subjects for this study and the rest
(n= 41), for whom complete amplifications of all exons was not
possible, were excluded. Table 1 shows the main characteristics of
these 119 patients. The mean age and the sex distribution are in
agreement with data previously reported from Golestan, where
there is an approximately equal incidence of ESCC in males and
females [16]. Of these patients, 65 (54.6%) were Turkmen and 54
(45.4%) were of non-Turkmen ethnicity, including Fars (26: 21.8%),
Balooch (4: 3.4%), Turk (15: 12.6%), Sistani (7: 5.9%) and Kurd (2:
1.7%). The proportion of Turkmens among the cases was similar to
the estimated proportion of ethnic Turkmens in the catchment area
of the case-control study (55%; unpublished data). All cancers were
invasive, with sizes ranging from 3 to 11 cm, including 89 patients
(83.2%) diagnosed with stage III or IV tumors.
Among well-documented risk factors for ESCC, information on
hot tea drinking was available for 106 subjects, among whom 43.4%
reported drinking tea 4 minutes or more after pouring. Only 4.2%
of patients reported ever using alcohol. The use of tobacco or opium
products in various forms (smoking or chewing) was reported by 52
subjects (43.7%), among whom 21 (17.6%) reported using both
substances. The majority of the subjects (71.4%) were from rural
areas, with farming and/or raising animals as the main occupations.
TP53 mutation analysis
Somatic TP53 mutations were confirmed in 107 patients
(89.9%) including nine patients with two different mutations and
two patients with three mutations (total: 120 mutations; see
detailed mutation description in Table S2). Figure 2A shows the
distribution of the types of the 120 mutations in exons 2 through
11 (including splice junctions). The most common mutation type
was G:C to A:T transitions (46; 38.3%), one third of them at CpG
dinucleotides (16; 13.3%), followed by G:C to T:A transversions
(20; 16.7%). Deletions represented 13.3% of all detected mutations
whereas other mutation types (G:C to C:G, mutations at A:T base
pairs) were less frequent. There was no association between
mutations and tumor grade or stage.
Codon distribution
Like previous studies, the majority of the mutations (101 out of
120; 84.2%) were detected in exons 5–8 (Figure 1). These included
mutations in exon 5 (29; 24.2%), exon 6 (25; 20.8%), exon 7 (25;
20.8%) and exon 8 (22; 18.3%). A total of 19 (15.8%) of the
mutations were detected on exons 4, 9 and 10 while no mutation
was found in exons 2 or 3. Only 9 (7.5%) of the mutations
occurred at ‘‘hotspot’’ TP53 codons (codons 175, 245, 273 and
282 where 20% of known TP53 mutations occur in all cancers).
No individual codon contained more than 4 mutations. Among
the G:C to T:A mutations, 8/20 (40%) occurred at codons
previously described as sites of PAH adduct formation which are
commonly mutated in lung cancer of smokers.
Comparing mutation patterns in Golestan and other
areas
Table 2 compares the patterns of mutations of ESCC from
Golestan with previously published mutation patterns from
Tehran. Since the previous studies examined only exons 5–8 of
TP53, for comparability, this part of analysis was done only on
mutations in these exons (101 of the total 120 mutations, Figure 1).
Figure 1. Flow chart summarizing the analyses carried out on
ESCC cases used from the Golestan Case-Control Study and the
number of mutations detected. Of a total of 160 cases, 119 were
fully sequenced for exons (Ex) 2–11 whereas 41 were either not
available (NA) or incompletely sequenced. Numbers of samples with
mutations (MT) or with wild-type TP53 (WT) are indicated. Among MT
cases, the number of cases with 1, 2 or 3 mutation(s) (mut) is given.
Below the dotted line, the total number of mutations (120) is broken
down into mutations in exons (Ex) 5 to 8 or in other exons.
doi:10.1371/journal.pone.0029488.g001
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To compare data from Tehran and Golestan, mutations were
categorized into six groups (Table 2), which showed a global p
(with 5 degrees of freedom) of 0.06. A difference was found
between the proportion of transition mutations at CpG dinucle-
otides in cases from the two areas (post-hoc analysis, p=0.002;
Table 2). Differences in the proportion of other mutations were
not significant. Figure 2B further illustrates the pattern of
mutations in exons 5–8 in Tehran, in Golestan, and in the Henan
Province of China, another area of high incidence. Of these three
patterns, the one of Henan showed the largest proportion of G:C
to T:A and G:C to C:G transversions (20.5% and 7%, respectively)
whereas the one of Tehran showed the lowest proportion of those
mutations (12% and 3.5%), respectively. With 17% and 5%,
respectively, the proportion of those transversions of Golestan was
somewhat closer to Henan than to Tehran. Furthermore, the
overall pattern of mutations in ESCC from Golestan was not
statistically different from the one of ESCC from Henan.
Association between mutations and risk factors
Table 3 compares the three most abundant mutation types to
the patient characteristics listed in Table 1. There was a small but
significant inverse association between age and G:C to T:A
transversions (using age as a continuous variable, adjusted OR:
0.93, 95% Cl, 0.88–0.99). Mutation types also showed differences
according to the temperature of tea consumption, with G:C to A:T
mutations at CpG sites being significantly more common among
hot tea drinkers (within 0–1 min of pouring) than among subjects
who drank tea at lower temperature ($4 minutes after pouring;
adjusted OR: 6.40, 95% CI, 1.16–35.16) Wild-type TP53 was
more common in hot tea drinkers (OR: 6.27, 95% CI, 1.04–
37.69). In contrast, G:C to T:A, G:C to C:G, A:T to G:C and A:T
to C:G mutations were found only in subjects who reported
drinking tea $2 minutes after pouring (Figure 3). Overall, these
observations suggest that there is an association between the
temperature of tea consumption and the presence and types of
TP53 mutation.
p53 protein expression
The expression of p53 protein was evaluated by IHC on
ethanol-fixed tumor tissue microarrays, using two antibodies, DO7
and 1801. Cores of 12 cases were lost during sectioning and/or
staining, so IHC was evaluable for only 107/119 cases. A good
agreement was found between the results of the two antibodies
(88.8% agreement with weighted k= 0.73). Of the 50 evaluable
Table 1. Number of participants and mutations by demographic, lifestyle, and tumor characteristics.
Charactersitica Subcategory
All participants
No (%b)
Participants with
mutation No (%c)
Total No. of
mutationsd
Mean age (SD); years 65.5 (11.0) 65.3 (11.0) -
Age group ,66 years 58 (48.7) 54 (93.1) 60
$66 years 61 (51.3) 53 (86.9) 60
Sex Women 60 (50.4) 52 (88.1) 62
Men 59 (49.6) 55 (91.7) 58
Ethnicity Non-Turkmen 54 (45.4) 50 (92.6) 58
Turkmen 65 (54.6) 57 (87.7) 62
Place of residence Rural 85 (71.4) 77 (90.6) 88
Urban 34 (28.6) 30 (88.2) 32
Alcohol drinking Never 114 (95.8) 103 (90.4) 115
Ever 5 (4.2) 4 (80.0) 5
Tobacco/opium use Neither 67 (56.3) 61 (91.0) 69
Tobacco 16 (13.5) 12 (75.0) 15
Opium 15 (12.6) 15 (100) 16
Both 21 (17.6) 19 (90.5) 20
Tea temperaturee $4 46 (43.4) 44 (95.7) 47
2–3 43 (40.6) 39 (90.7) 45
0–1 17 (16.0) 13 (76.5) 15
Tumor size ,5 cm 27 (24.7) 25 (92.6) 28
5–8 cm 67 (61.5) 62 (92.5) 70
.8 cm 15 (13.8) 12 (80.0) 14
Tumor stage I 4 (3.8) 3 (75.0) 3
II 14 (13.0) 12 (85.7) 14
III 37 (34.6) 32 (86.5) 38
IV 52 (48.6) 49 (94.2) 55
aBecause of missing values, the total number of participants for some variables is less than 119.
bColumn percentages.
cRow percentages.
dThe total number of mutations was 120, detected in 107 participants (see Figure 1).
eEstimated by the time interval between tea being poured and drunk (in minutes).
doi:10.1371/journal.pone.0029488.t001
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cases with missense mutation, 41 (82%) were positive for p53
(strong or moderate staining) and 9 were negative (negative or
weak staining). In contrast, among cases with mutations predicting
absence of p53 protein (nonsense, splice, or frameshift mutations),
28 (77.8%) of 36 evaluable cases were negative (no or weak
staining), whereas only 8 (22.2%) were positive (strong or
moderate staining) (Table S3). Thus, overall, there was a highly
significant association between the presence of missense mutation
and p53 expression scores (p,0.001), and there was a strong
association between nonsense/splice/frameshift mutations and
lack of p53 expression (p=0.013/p=0.005/p=0.018 respectively).
Discussion
ESCC is by far the most common cancer in both males and
females in Northern Iran as well as in large parts of Central Asia
[9]. The main challenge to reduce the incidence and the mortality
of this extremely lethal disease is to develop prevention strategies
based on a precise understanding of environmental causes. As an
approach to identify new clues for the mechanisms of mutagenesis
leading to ESCC in that part of the world, we have analyzed for
Figure 2. Distribution of TP53mutation types in ESCC. A: TP53 Mutation types in ESCC from Golestan, exons 2 to 11. Mutations are grouped in
categories as defined in the IARC TP53 mutation database (http://www-p53.iarc.fr). B: Comparison of mutation types in exons 5 to 8 of ESCC from
Golestan (this study, n = 101) with results from Tehran (n = 85) and Henan Province, China (n = 117) compiled in the IARC TP53 mutation database
(http://www-p53.iarc.fr/AdvancedCriteria.asp; search criteria: Esophagus, exons 5 to 8, Squamous Cell Carcinoma, surgery or biopsy, DNA; for China:
Linxian and/or Henan, for Iran: Tehran).
doi:10.1371/journal.pone.0029488.g002
Table 2. Comparison between TP53 mutation patterns in
ESCC of patients from Golestan and Tehrana.
Mutation Type N6 (%) Gonbad N6 (%) Tehran p-value(b)
A:T.C:G 8 (7.9) 4 (4.7) 0.920(c)
A:T.G:C 11 (10.9) 9 (10.6)
A:T.T:A 3 (3.0) 5 (5.9)
Others 16 (15.8) 11 (12.9) 0.576
G:C.A:T 26 (25.7) 14 (16.5) 0.125
G:C.A:T at CpG 15 (14.8) 29 (34.1) 0.002
G:C.C:G 5 (5.0) 3 (3.5) 0.634
G:C.T:A 17 (16.8) 10 (11.8) 0.328
a: data for Tehran are from Sepehr et al., 2001 and Biramijamal et al. 2001 (see
text).
b: p for the difference in prevalence of mutations in exons 5 through 8 in
Golestan and Tehran, calculated by using the Pearson chi-square test.
c: p for all types of mutations at A:T base pairs (often interpreted as caused by
acetaldehyde, a metabolite of alcohol) taken as a single category.
doi:10.1371/journal.pone.0029488.t002
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the first time the patterns of mutations in the tumor suppressor
gene TP53. All mutations were identified by direct sequencing and
were confirmed by at least one second independent sequencing of
a distinct PCR product. In this study, fixation procedures and
timing were also carefully controlled. Moreover, statistical analysis
did not show any association between mutation type and type of
fixative, even after adjustment for age, sex, ethnicity, place of
residence, tobacco/opium use and tea consumption time (data not
shown). Thus, the mutations reported here are unlikely to be
biased by sequencing or tissue fixation artifacts.
We detected at least one mutation in 89.9% of the cases (107/
119), a prevalence which is, to our knowledge, the highest ever
reported in any cancer anywhere. For comparison, cancers with
particularly high mutation rates include lung cancers of very heavy
smokers (80%; reviewed in reference [11]) or liver cancers in
subjects heavily exposed to aflatoxin (60–75%; reviewed in
reference [17]). In ESCC from other areas of the world,
prevalence varying between 35% (Lyon, Southeastern France)
[18] and 80% (Normandy, Northwestern France) [19] have been
reported. Mutation prevalence appears to be consistently high in
areas of high incidence, as for example parts of China [20] or
Southern Brazil [21,22]. Two previous studies on ESCC cases
recruited in Tehran showed a mutation prevalence of 50%,
[14,15] substantially lower than the prevalence we found in our
cases from Golestan. Moreover, in Golestan, 10% of patients with
mutations showed more than one mutation in TP53.
The TP53 mutation pattern in ESCC from Golestan is
heterogeneous, with fewer than 10% of the mutations occurring
at TP53 ‘‘hotspot’’ codons (for reference mutation patterns see
IARC TP53 database at http://www.iarc.fr/p53). The most
common mutation type was G:C to A:T transitions at positions
that do not contain CpGs, a type of mutations which can be
induced by multiple mechanisms and is therefore difficult to assign
to any specific risk factor. In vitro, there is experimental evidence
that guanines in such positions are targeted for adduct formation
by nitrosamines such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) [23]. Interestingly, a high proportion of G:C to
A:T transitions has also been observed in ESCC in other areas of
high incidence [20–22]. Overall, mutations attributable to
endogenous mutagenic processes were infrequent; for example,
G:C to A:T mutations at CpG sites, a type of mutation which often
occurs as the result of spontaneous deamination of 59methylcyt-
osine, represented only 13.3% of all mutations, in contrast to 25%
of mutations in all cancers compiled in the TP53 mutation
database (n = 26597) and 33% of the mutations in ESCC cases
from Tehran (n= 85) [14,15]. On the other hand, transversion
mutations, which often occur as the result of mutagenesis by
carcinogens forming bulky DNA adducts, represented about 30%
of all mutations. Among those, the most common type was G:C to
T:A. This type of mutation is frequent in tumor types where PAHs
play an important role, such as lung cancer in smokers [11]. In the
present series, although G:C to T:A transversions are less frequent
than in lung cancers of smokers [13], 40% of them occurred at
codons described as sites of adduction of PAH. Interestingly,
mutations at these sites were not observed in ESCC cases from
Tehran [15]. Several lines of evidence have suggested a role for
polycyclic aromatic hydrocarbons (PAHs) in the etiology of ESCC
in Golestan. Dietary intake of benzo[a]pyrene (B[a]P) has been
reported to be higher than in lower-risk Fars Province [24]. High
levels of 1-hydroxypyrene glucuronide (1-OHPG), a biomarker of
PAH exposure, were detected in urine samples in 83% of
participants from Golestan [25]. In a recent study, we used
antibodies to PAH-adducts to assess exposure in biopsies of
histopathologically normal esophagus from ESCC cases and
controls from Golestan. We found a strong and significant
association between the intensity of staining and case status
(adjusted OR for the 5th quintile: 26.6 (95% CI, 5.21 to 135); p for
trend ,0.001) [26]. Our mutation data are consistent with a role
for PAH in mutagenesis in ESCC in Golestan. However, the
heterogeneity of the mutation pattern suggests that PAHs are only
one of several types of mutagens and that other still-unidentified
factors may play additional or independent roles.
PAHs are common agents produced during incomplete
combustion of organic materials. Their major sources other than
tobacco smoke are food products [27], air pollution [28] and
occupational [29] exposures. IARC has classified B[a]P and
several PAH mixtures as group 1 carcinogen for humans [30].
Further studies are needed to identify the source(s) of PAH
associated with risk of ESCC in the population of Golestan.
Detailed analysis of the mutation pattern did not support the
association of mutations with sex, tobacco or opium use, alcohol
consumption, ethnicity, or urban vs. rural residence. A small but
significant reduction in the rate of G:C to T:A transversions was
observed with increasing age, suggesting that this type of
mutation might be more common in cancers that develop at an
early age. However, the biological basis of this association is not
known.
The absence of association with opium deserves comment, since
consumption of opium pyrolysates has been shown to be a risk
factor in Golestan, and these pyrolysates contain a number of
carcinogens including PAHs [31,32]. In the current study, 36
patients reported using opium, including 21 who also reported
tobacco use. Of the 15 patients who used only opium, all had a
mutation in TP53, although the types of mutations were not
significantly different than in patients who did not report opium
use. This low number of patients reporting opium use is unlikely to
be due to a reporting bias, since a previous study in a cohort
setting in Golestan has confirmed the validity of this self-reported
information using urinary metabolites as a control [33]. It should
be noted that there is no evidence that opium usage leads to the
formation of a particular type of mutation. Furthermore, the small
number of opium users in this study may not be sufficient to detect
an effect on mutation type, if any exists.
Figure 3. Distribution of TP53 mutation types in ESCC from
Golestan according to tea temperature. Tea temperature was
estimated by the time interval between pouring and drinking tea (from
0–1 min to 4 min or more). Mutations are grouped in categories as in
Figure 2. *: OR: 6.27, 95% CI, 1.04–37.69 for wild-type TP53 in Group 0–
1 min as compared to Group 4 min or more; **: OR: 6.40, 95% CI, 1.16–
36.16 for G:C to A:T at CpG in Group 0–1 min as compared to Group
4 min or more. Note the absence of G:C to T:A, G:C to C:G, A:T to G:C
and A:T to C:G mutations in Group 0–1 min.
doi:10.1371/journal.pone.0029488.g003
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Our study revealed different mutation patterns related to tea
drinking habits. Wild-type TP53 and G:C to A:T transitions (in
particular at CpG sites) were most often seen in subjects who
reported drinking tea within 1 minute of pouring. Conversely,
transversion mutations (including G:C to T:A mutations) were
observed only in subjects who reported a preference for drinking
tea with a longer delay (at least 2 minutes after pouring). A
previous study has shown that this method of measuring time-to-
drinking intervals was a reliable surrogate for actual tea
temperature. Using this method, Islami et al., (2009) have shown
that tea temperature was a significant risk factor for ESCC in
Golestan [7]. Our results further suggest that tea temperature
affects mutagenic processes in this population. Surprisingly
patients with wild-type TP53 were exclusively found among
drinkers of hot tea, suggesting that thermal injury may represent a
very potent carcinogenic mechanism that do not require TP53
mutation. On the other hand, time after pouring may affect the tea
concentration in potential mutagens derived from tea leaves, as
well as the release of other toxic agents (e.g. metal ions) from tea
containers. Hot temperature may also affect tissue permeability,
tissue damage and healing of the esophageal epithelium, thus
modulating the way in which the epithelium acts as a barrier to
carcinogens from tea or other sources [34].
A comparison between mutation patterns in Golestan and other
areas of the world is only possible for mutations in exons 5–8,
which are the only exons that have been analyzed in the majority
of previously published studies (see Figure 2B). This comparison
shows that the mutations in ESCC from Golestan are different
from the ESCC mutations seen in Tehran, strengthening the
hypothesis of specific risk factors in Golestan. The differences were
less marked between the patterns of mutations in ESCC from
Golestan and from Henan Province, China, another high
incidence area. Interestingly, there are similarities between the
epidemiology of ESCC in Golestan and in central China. In
particular, high levels of PAHs have been identified in food from
Linxian, Henan Province, and these carcinogens have also been
proposed to contribute to that region’s high incidence of
esophageal cancer [35].
In conclusion, this study shows an extremely high prevalence of
diverse types of TP53 mutations in ESCC tumors from Golestan.
Most of these mutations are missense, leading to the accumulation
of mutant p53 protein. Thus, ESCC from Golestan might be
responsive to treatment by drugs that rescue p53 protein function,
such as PRIMA-MET, a drug that has been shown to induce
massive apoptosis in cells that express mutant p53 proteins [36].
The complex mutation pattern cannot be ascribed to a single
category of mutagens. A plausible model for ESCC carcinogenesis
in this area may be that the population at risk is exposed to
multiple factors that damage the esophageal mucosa (e.g. thermal
stress, toxic agents or irritants). In such conditions, tissue healing
and the DNA repair capacity of epithelial cells may be diminished,
making them susceptible to mutagenesis caused by different types
of carcinogens, even if present at only moderate levels. In the case
of the most severe forms of thermal stress (the drinkers of hot tea),
the contribution of such carcinogens may even be limited (as
suggested by the high proportion of patients with wild-type TP53
or with CpG mutations). Further studies are needed to analyze in
detail the mechanisms causing the extremely high load of TP53
mutation observed in ESCC cases from Golestan and to assess
whether similar mechanisms may characterize ESCC carcinogen-
esis throughout the so-called ‘‘Central Asian Esophageal Cancer
Belt’’, an area encompassing several populations and extending
from the Caspian Sea to the Sea of China in which ESCC is the
most frequent type of cancer.
Materials and Methods
Ethics statement
Written consent was obtained from all participants in the
Golestan Case-Control Study (GCCS) and this study was
approved by the Institutional Review Boards of the United States
National Cancer Institute (US NCI), IARC and the Digestive
Disease Research Center (DDRC) of Tehran University of
Medical Sciences (TUMS).
Cases and tissue selection
ESCC cases came from the Golestan Case-Control Study
(GCCS), a study conducted between 2003 and 2007. GCCS is part
of the GEMINI project (Gastro-Eesophageal Malignancies In
Northern Iran), a group of collaborative studies between US NCI,
IARC and DDRC of TUMS. The study design, objectives and
methods of the GCCS have been published previously [5,9,37].
The catchment area of the GCCS covered the urban and rural
areas of Gonbad, Kalaleh, Minoodasht districts in the eastern part
of Golestan. The population of these areas is about 50% ethnic
Turkmens, a group of several tribes of central Asian ancestry in
whom ESCC has been reported to be very frequent. The other
50% of the population includes different ethnic groups, mainly
Fars, Turks and Baloochs. During interviews conducted in the
case-control study, individual information was collected on
demographics, nutrition, occupation, diet and lifestyle habits. In
the present study, we included the following variables: age, sex,
ethnicity (Turkmen/non-Turkmen); tobacco consumption (ever/
never), opium consumption (ever/never), alcohol consumption
(ever/never), tea temperature (estimated by the time interval
between tea being poured and drunk, and categorized in minutes)
and residence (urban/rural). Data on daily amount of tea
consumption were not collected. Of note, the method for scoring
tea temperature has been validated in a previous study which
reported a strong agreement between responses to the questions on
temperature at which tea was drunk and interval from tea being
poured to being drunk (weighted kappa 0.68). [7] The GCCS
recruited a total of 300 histologically confirmed ESCC cases. One
hundred and sixty cases were chosen for this study based on
available biopsies. To be included, a case must have had at least
one large endoscopic tumor biopsy with at least 70% tumor cells.
Biopsies were obtained in the course of chromoendoscopy using
Lugol’s iodine, fixed in 10% buffered formalin or 70% ethanol and
embedded in paraffin. Diagnosis has performed independently by
two pathologists on heamatoxylin-eosin (H&E) stained slides.
Analysis of TP53 mutations
Biopsies containing at least 70% of tumor cells (as determined
by examination of H&E sections) were deparaffinized and DNA
was extracted using QIAamp DNA MicroKit from QIAGEN
(Hilden, Germany) as described by the manufacturer. TP53
mutation analysis of exons 2 through 11 was performed by direct
sequencing of PCR products encompassing the entire coding
sequence and splice junctions. Sequencing was performed on an
Applied Biosystems PRISM 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA). Each PCR product was generated in
duplicate, with one product sequenced in the forward direction
and the other in the reverse direction. In the case of discordant
sequencing results, the complementary sequences were analyzed
and the final result was confirmed by sequencing a third,
independent PCR product. Primers, PCR and sequencing
conditions have been described in detail and are available on
the TP53 IARC database website at http://www-p53.iarc.fr/
Download/TP53_DirectSequencing_IARC.pdf. Chromatograms
TP53 Mutations in Esophageal Cancer in Iran
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e29488
were analyzed semi-automatically by visual inspection of sequenc-
es imported in sequence analysis software Seqscape (Applied
Biosystems) using the reference sequence NC_000017.9 from
Genbank (http://www-p53.iarc.fr/TP53sequence_NC_000017-9.
html). Variations were checked with the mutation validation tool
available at http://www-p53.iarc.fr/MutationValidationCriteria.
asp. For comparison of results with sequencing data from ESCC
from other geographic areas, the IARC TP53 mutation database
(version R15, November 2010, http://www.iarc.fr/p53) was used
(Table S1).
Immunohistochemistry
p53 protein expression was evaluated by IHC using two
monoclonal antibodies, DO7 and 1801 which recognize distinct
epitopes in the N-terminal domain of p53. Tumor tissue micro-
arrays were prepared as previously described [26]. After depar-
affinization and rehydration, antigen retrieval was carried out for
20 minutes using Trilogy solution (Cell Marque) in a steamer
(95uC). Endogenous peroxidases were blocked with 3% H2O2 in
methanol for 5 minutes. Sections were processed in an automated
Dako stainer, with the following steps: incubation with primary
antibodies (DO7, Dako; 1:50, 30 minutes or 1801, Oncogene
Science; 1:40, 1 hour) at room temperature; incubation with the
secondary antibody (Goat anti-Mouse, peroxidase-coupled, Dako,
1:250) for 15 min at room temperature and visualization using 3, 39-
diaminobenzidine solution (DAB) for 15 minutes. Expression was
scored using a composite score in which the percentage of stained
tumor cells was evaluated on a scale from 0 to 4 (0: No staining; 1:
1–25%; 2: 26–50%, 3: 51–75%; 4: 76–100%) and the intensity of
staining was assessed on a scale from 0 (Negative) to 3 (strong). The
two scores were multiplied to generate a composite score (0–12)
categorized in 4 groups: 0 = negative; 1–4=weak; 5–8=moderate;
and 9–12= strong.
Statistical analysis
Stata Version 11 (StataCorp LP, College Station, TX) was used
to conduct all statistical analyses. Two-sided P,0.05 was
considered as statistically significant. Age was included in our
analyses separately as continuous and categorical variables (greater
than or equal to versus less than the median age (66 years)).
Consistent with our previous studies, tea temperature was
estimated by the time interval between tea being poured and
drunk, and was categorized as 0–1, 2–3, and 4 minutes or more
[7]. Tobacco and opium use variables were combined and
categorized as never-use of tobacco and opium, ever-use of
tobacco only, ever-use of opium only, and ever-use of both tobacco
and opium [5]. The distribution of mutation types in Golestan was
compared with those in Tehran and a high incidence area of
China (Henan Province) using chi-square tests (data selected from
the IARC TP53 mutation database; http://www-p53.iarc.fr ).
Odds ratios (OR) and 95% confidence intervals (CI) were
calculated for the association between several patient character-
istics and risk of selected mutations using multivariate logistic
regression models, in which the following variables were included:
age (continuous), sex, ethnicity (Turkmen vs. non-Turkmen), place
of residence (urban vs. rural), tobacco and/or opium use, and tea
temperature (time interval between tea being poured and drunk).
For IHC, the agreement between results from the two anti-p53
antibodies was calculated with a weighted kappa statistic. The
association between the presence of mutations and the results of
IHC was examined using chi-square tests.
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